Sputnik V vaccine shows 92 per cent efficacy in peer-reviewed trial

By - World Healthcare Journal

Sputnik V vaccine shows 92 per cent efficacy in peer-reviewed trial

The Russian-made Sputnik V vaccine has been proven to provide around 92 per cent protection against Covid-19, as revealed in the results of a late-stage trial, published in The Lancet.

In addition to the high efficacy of the vaccine, the study also revealed it is safe for use and provides complete protection against severe cases of Covid-19.

The vaccine was previously criticised for its rollout ahead of Phase III trial data - however, this review indicates that it may have been a justifiable approach.

"The development of the Sputnik V vaccine has been criticised for unseemly haste, corner-cutting, and an absence of transparency. ”, Professor Ian Jones and Professor Polly Roy stated in a comment released alongside the review.

"But the outcome reported here is clear and the scientific principle of vaccination is demonstrated, which means another vaccine can now join the fight to reduce the incidence of Covid-19".

The vaccine now joins AstraZeneca/Oxford, Pfizer/BioNTech, Moderna and Janssen in the proven effective vaccines against Covid-19.

"The publication of internationally peer-reviewed data on SputnikV's clinical trial results is a great success in the global battle against the Covid-19 pandemic,” says Alexander Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology.

“The Russian vaccine's safety and high efficacy are shown by the hard scientific data presented and I congratulate the entire team of Gamaleya National Research Center for this monumental achievement. Several vaccines have already been created based on human adenoviruses and this tool is one of the most promising for development of new vaccines in the future,” he added.

The Sputnik V vaccine works in a similar way to the Oxford/AstraZeneca vaccine, using a harmless virus to expose the immune system to a piece of Covid-19’s genetic code. After vaccination, the body begins to produce Covid-19 antibodies to attack the virus - which the immune system will do again if encounters the real virus.

Sputnik V is the only vaccine of this type to reach the same efficacy rate as the mRNA vaccines, which do not use a harmless virus to provide immunity, but have displayed higher effectiveness in trials.

"Presently, the world needs all the good vaccines that it can get against COVID-19. And these are impressive results: Sputnik V is the first adenovirus vector vaccine to achieve the 90 per cent efficacy seen with the two mRNA vaccines,” said David Livermore, Professor of Medical Microbiology at the University of East Anglia.

#whjnews #whjvaccine #coronavirus #whjfabiansutch